

## Supplementary material

**Article type** | Narrative review

**Title** | A review of MAL-PDT for the treatment strategy of actinic keratosis: Broader clinical perspectives beyond the data and guideline recommendations

Szeimies R-M,<sup>1</sup> Dirschka T,<sup>2</sup> Fagnoli MC,<sup>3,4</sup> Gilaberte Y,<sup>5</sup> Hædersdal M<sup>6</sup>, Chavda R,<sup>7</sup> Calzavara-Pinton P<sup>8\*</sup>

<sup>1</sup>Department of Dermatology and Allergology, Klinikum Vest GmbH Academic Teaching Hospital, Recklinghausen, Germany; <sup>2</sup>CentroDerm Clinic, Wuppertal, Germany; <sup>3</sup>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; <sup>4</sup>Dermatology Unit, San Salvatore Hospital, L'Aquila, Italy; <sup>5</sup>Department of Dermatology, Miguel Servet University Hospital, IIS Aragón, Zaragoza, Spain; <sup>6</sup>Department of Dermatology, Bispebjerg and Frederiksberg Hospitals, Copenhagen University Hospital, Copenhagen, Denmark; <sup>7</sup>Galderma SA, Switzerland; <sup>8</sup>Dermatology Department, University of Brescia, Brescia, Italy

\*Corresponding author: Piergiacomo Calzavara-Pinton

Email address: piergiacomo.calzavarapinton@unibs.it

Correspondence address: Piazza Spedali Civili 1, 25123 Brescia

**Table S1. PubMed search strings utilized to search MEDLINE.**

Search date	Search string	Total number of results	Number of results after exclusions*
24 October 2022	((methyl aminolevulinate[Title] OR (MAL[Title])) AND ((actinic keratos*[Title] OR (AK[Title] OR (solar keratos*[Title]))	37	37
24 October 2022	((methyl aminolevulinate[Title] OR (MAL[Title])) AND (long term efficacy)	14	13
24 October 2022	((methyl aminolevulinate[Title] OR (MAL[Title])) AND (efficacy) AND (chronic)	6	4
24 October 2022	((methyl aminolevulinate[Title] OR (MAL[Title])) AND (field cancerization)	17	16
24 October 2022	((methyl aminolevulinate[Title] OR (MAL[Title])) AND (5-fluorouracil)	5	5
24 October 2022	((methyl aminolevulinate[Title] OR (MAL[Title])) AND ((photodynamic therapy) OR (PDT))	147	141
24 October 2022	((methyl aminolevulinate[Title/Abstract] OR (MAL[Title/Abstract])) AND (off label)	10	5
24 October 2022	((methyl aminolevulinate[Title] OR (MAL[Title])) AND (patient[Title/Abstract])	95	90
24 October 2022	(delay* onset[Title/Abstract] AND (actinic keratosis)	2	2
24 October 2022	(delay* onset[Title/Abstract] AND ((photodynamic therapy) OR (PDT))	16	16
25 October 2022	(actinic keratos*[Title] AND ((guideline*[Title] OR (consensus[Title]))	39	36
25 October 2022	(actinic keratos*[Title] AND ((photodynamic therapy[Title] OR (PDT[Title]))	294	274

\*exclusion terms were “NOT acne vulgaris” and “NOT United States”.

**Table S2. Selected PubMed filters utilized to search MEDLINE.**

Article type	Age	Sex	Species
Clinical study	Adults: 19+ years	Female	Humans
Clinical trial	Young adult: 19–24 years	Male	
Congress	Adult: 19–44 years		
Consensus development conference	Middle aged + aged: 45+ years		
Guideline	Middle aged: 45–64 years		
Journal article	Aged: 65+ years		
Meta-analysis	80 and over: 80+ years		
Multicenter study			
Practice guideline			
Randomized controlled trial			
Review			
Systematic review			

English language publications between January 01, 2010 and October 25, 2022 with all the above filters were searched.